Alivus Life Sciences Reports Strongest Performance Ever, Delivering Record Revenues of Rs 6,729 Mn and Highest Ever EBITDA Margins of 36.4%

Alivus Life Sciences Limited, a leading developer and manufacturer of select, high-value, non-commoditized, Active Pharmaceutical Ingredients (APIs) in chronic therapeutic areas, announced its financial results for the quarter and nine months ended December 31, 2025. The company reported record revenues of Rs. 6,729 Mn for Q3FY26, a growth of 14.4% QoQ and 4.8% YoY. EBITDA was at Rs. 2,452 Mn, a growth of 26.5% QoQ and 22.1% YoY. EBITDA margins were at a record high of 36.4%, up 340 bps QoQ and 510 bps YoY. PAT for Q3FY26 stood at Rs. 1,503 Mn, a growth of 15.5% QoQ and 9.7% YoY. The company generated a strong free cash flow of Rs. 2,207 Mn leading to Cash and Cash Equivalents of Rs. 7,330 Mn as of December 31, 2025. The performance was led by a favourable product mix, strong recovery in the CDMO business, increased contributions from new product launches, and continued gains in operational efficiency.